X
KEY SERVICES
Details:
Under the collaboration, FAMAR will undertake the production of two pharmaceutical products recently added to Lavipharm’s portfolio of analgesic pharmaceutical products, Lonarid N (paracetamol) and Lonalgal (caffeine Anhydrous).
Lead Product(s): Paracetamol,Caffeine
Therapeutic Area: Immunology Product Name: Lonarid N
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: LaviPharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 23, 2024
Details:
Under the agreement, Medicom has acquired the ownership of the pharmaceutical dossier of Zimed (bimatoprost), a preservative free eye drop solution, which is already registered in the UK and 5 EU countries with plans to commercialise the asset globally.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: Zimed
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Medicom Healthcare
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 09, 2021
Details:
Through the agreement, Active Biotech will get the material for the clinical development of the eye-drop formulation of ABR-215062 (laquinimod), which is used for the treatment of non-infectious non-anterior uveitis.
Lead Product(s): Laquinimod
Therapeutic Area: Ophthalmology Product Name: ABR-215062
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Active Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 04, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
FAMAR CDMO- From early development to commercial manufacturing.
